GRFS logo

GRIFOLS SA-ADR

GRFSNASDAQ
Earnings Nov 10US Equity
$7.91β–Ό $0.08 (βˆ’1.00%)
Live
1hβ–Ό 0.1%
24hβ–Ό 1.0%
7dβ–Ό 0.4%
14dβ–Ό 2.7%
30dβ–² 10.1%
1yβ–Ό 25.4%
🏦Market Cap
$5.44B
Small Cap
πŸ“ˆRevenue Growth (YoY)
-0.3%
Declining
πŸ“ŠGross Margin
37.0%
Healthy
πŸ’΅FCF Margin
8.7%
Moderate
βš–οΈP/S Ratio
0.8x
Cheap
Otter Score
64
Fair

Trading Snapshot

Day Range
$7.85 – $7.99
52-Week Range
β€”
Volume
$3.76B
Avg Volume
$3.88B
Shares Outstanding
687.5M
Next Earnings
Sep 20, 2026

Fundamentals Snapshot

Annual Revenue
$7.23B
Last Q Revenue
$1.87B
P/E Ratio
13.4
P/S Ratio
0.8x
EPS (TTM)
β€”
Dividend Yield
2.11%

Why Investors Own GRFS

  • βœ“High-growth profile β€” revenue up +16.7% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 70% gross margin and 8% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$7.23Bβ–² +12.0% YoY
Gross Margin (TTM)
70.4%β–² +1.2% YoY
Operating Income (TTM)
$2.48Bβ–² +12.0% YoY
Free Cash Flow (TTM)
$578Mβ–² +12.0% YoY

About GRIFOLS SA-ADR

Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunoglobulins, alpha-1 antitrypsin, albumin, and clotting factors, along with other innovative treatments for chronic, rare, prevalent, and life-threatening conditions. The Hospital division provides non-biological pharmaceuticals, medical supplies, clinical nutrition solutions, intravenous therapies, and medical devices. The Diagnostic division develops, manufactures, and commercializes diagnostic products that span the entire healthcare continuum, from prevention and screening to diagnosis, prognosis, and monitoring of diseases and treatments, catering to professional healthcare providers. The Bio Supplies division offers essential biological materials for life-science research, clinical trials, and the manufacturing of pharmaceutical and diagnostic products. These diverse offerings enable healthcare professionals to diagnose and treat patients suffering from conditions like hemophilia, immune deficiencies, and infectious diseases. Grifols serves a wide array of clients, including public and private healthcare organizations, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, and national health systems. The company also maintains a technology collaboration agreement with Mondragon.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
64/100

Analyst Ratings

β“˜
Consensus
Buy
21 analysts
Strong Buy5
Buy9
Hold5
Sell2
Strong Sell0
Ratings as of Aug 2026

Latest News & Updates

YahooΒ·7d ago

European Equities Traded in the US as American Depositary Receipts Edge Up in Wednesday Trading

European equities traded in the US as American depositary receipts were edging higher late Wednesday

YahooΒ·14d ago

FOXO TECHNOLOGIES INC.’S SUBSIDIARY VECTOR BIOSOURCE, INC. ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE FOUR BLOOD COLLECTION CENTERS FROM GRIFOLS BIO SUPPLIES, INC.

WEST PALM BEACH, FL, July 29, 2026 (GLOBE NEWSWIRE) -- FOXO Technologies Inc.’s (OTC: FOXOD/FOXO) ( β€œFOXO”) subsidiary, Vector BioSource, Inc. (β€œVector”) today announced that it has entered into a definitive agreement to acquire four U.S.-based blood collection centers (the β€œAgreement”) from Grifols Bio Supplies, Inc., a U.S.-based subsidiary of Grifols S.A. The acquisition is intended to provide a proprietary source of bio-products to sell to Vector’s customers to augment its existing sourcing

YahooΒ·14d ago

Grifols (GRFS) Q2 2026 Earnings Call Transcript

CEO Abia discusses immunoglobulin growth and Egypt plasma expansion strategy.

YahooΒ·14d ago

Grifols SA (GRFS) (H1 2026) Earnings Call Highlights: Strong Biopharma Growth and Strategic ...

Grifols SA (GRFS) reports robust revenue growth and strategic progress, despite facing temporary challenges in key markets.

SeekingAlphaΒ·14d ago

Grifols, S.A. (GIKLY) Q2 2026 Earnings Call Transcript

Grifols, S.A. (GIKLY) Q2 2026 Earnings Call July 28, 2026 12:30 PM EDTCompany ParticipantsDaniel Segarra - Head of Investor Relations & Sustainability...

YahooΒ·14d ago

Grifols Q2 Earnings Call Highlights

Grifols (NASDAQ:GRFS) said its second-quarter and first-half results kept the plasma-derived medicines company on track to meet its 2026 objectives, supported by continued growth in immunoglobulins, improving free cash flow and progress in its plasma-sourcing strategy. Chief Executive Officer Nacho